PRME
Prime Medicine Inc
NASDAQ · Biotechnology
$3.57
+0.33 (+10.19%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 4.55M | 5.48M | 82.53M | 80.41M | 91.62M |
| Net Income | -298,131,393 | -323,119,284 | -23,543,617 | -21,315,556 | -21,784,047 |
| EPS | — | — | — | — | — |
| Profit Margin | -6,566.6% | -6,238.3% | -28.5% | -26.5% | -23.8% |
| Rev Growth | -17.0% | -17.0% | +18.1% | +23.7% | +18.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 201.88M | 163.97M | 189.68M |
| Total Equity | — | — | 348.22M | 325.63M | 311.28M |
| D/E Ratio | — | — | 0.58 | 0.50 | 0.61 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -298,763,181 | -341,793,138 | -26,937,435 | -26,154,771 | -26,439,424 |
| Free Cash Flow | — | — | -11,662,926 | -13,660,015 | -13,547,044 |